Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite,
ACP
‐5862, Using a
Physiologically‐Based Pharmacokinetic
Modeling Approach
2019 ◽
Vol 8
(7)
◽
pp. 489-499
◽
2016 ◽
Vol 55
(11)
◽
pp. 1435-1445
◽
2016 ◽
Vol 5
(5)
◽
pp. 250-257
◽
2017 ◽
Vol 40
(12)
◽
pp. 1356-1379
◽
2014 ◽
Vol 35
(9)
◽
pp. 543-552
◽
2014 ◽
Vol 63
◽
pp. 103-112
◽
2012 ◽
Vol 33
(2)
◽
pp. 111-121
◽